DANA NORRIS: Open Payments
NPI 1356433064 · FAYETTE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$174 in 9 payments from 8 companies in 2025. Trend: 2023 $88 · 2024 $193 · 2025 $174
Food & beverage: $174
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $35 |
| Atland Pharmaceuticals, LLC | 1 | $29 |
| ABBVIE INC. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Corcept Therapeutics | 1 | $16 |
| Novo Nordisk Inc | 1 | $16 |
Products named: CAPLYTA, ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE, VRAYLAR, REXULTI, MOUNJARO, GVOKE HYPOPEN, Korlym, Wegovy.
Industry payments across AL — which companies pay providers there.
